PDL BioPharma Inc (NASDAQ:PDLI) shares reached a new 52-week high during trading on Monday . The stock traded as high as $3.85 and last traded at $3.83, with a volume of 24622 shares traded. The stock had previously closed at $3.80.

PDLI has been the subject of several research analyst reports. ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a research report on Tuesday, March 12th. BidaskClub upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a report on Friday, January 4th. TheStreet upgraded PDL BioPharma from a “d+” rating to a “c-” rating in a report on Wednesday, February 6th. Finally, Zacks Investment Research upgraded PDL BioPharma from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $3.00.

The firm has a market cap of $484.26 million, a PE ratio of 10.22 and a beta of 0.59. The company has a quick ratio of 9.50, a current ratio of 9.86 and a debt-to-equity ratio of 0.17.

PDL BioPharma (NASDAQ:PDLI) last released its earnings results on Thursday, March 14th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.02. The firm had revenue of $45.12 million during the quarter. PDL BioPharma had a positive return on equity of 6.76% and a negative net margin of 34.76%. During the same quarter last year, the business posted $0.15 earnings per share. As a group, analysts expect that PDL BioPharma Inc will post 0.25 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in PDL BioPharma by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 1,910,568 shares of the biotechnology company’s stock valued at $5,540,000 after buying an additional 45,573 shares in the last quarter. Millennium Management LLC raised its stake in PDL BioPharma by 46.1% in the fourth quarter. Millennium Management LLC now owns 293,842 shares of the biotechnology company’s stock valued at $852,000 after buying an additional 92,697 shares in the last quarter. Weber Alan W acquired a new stake in PDL BioPharma in the fourth quarter valued at $580,000. Legal & General Group Plc raised its stake in PDL BioPharma by 24.2% in the fourth quarter. Legal & General Group Plc now owns 26,678 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 5,197 shares in the last quarter. Finally, Ancora Advisors LLC raised its stake in PDL BioPharma by 73.3% in the fourth quarter. Ancora Advisors LLC now owns 472,507 shares of the biotechnology company’s stock valued at $1,370,000 after buying an additional 199,800 shares in the last quarter. Hedge funds and other institutional investors own 93.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “PDL BioPharma (PDLI) Reaches New 12-Month High at $3.85” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/pdl-biopharma-pdli-reaches-new-12-month-high-at-3-85/2952931.html.

PDL BioPharma Company Profile (NASDAQ:PDLI)

PDL BioPharma, Inc acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally.

Recommended Story: Producer Price Index (PPI)

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.